Literature review reports delayed palliative androgen deprivation via metastasis-directed therapy in oligometastatic prostate cancer, highlighting the need for standardized clinical trials.
The article is dedicated to the modern methods of diagnosis and treatment of oligometastatic prostate cancer based on a large amount of literature data. The main goal of metastasis-directed therapy in oligometastatic prostate cancer is slowing of metastatic process, increased time to palliative androgen deprivation therapy, and cure of the patient. Currently, there is not enough high-quality data on treatment and effectiveness of metastasis-directed therapy. Terminology standardization, use of the full potential of positron emission tomography/computed tomography imaging with prostate-specific membrane antigen, its combination with molecular and genetic tests, and stratification of risk factors for each individual patient are necessary.
No takes yet. Share an insight, caveat, or question.
Тер-Ованесов et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: